CoA Therapeutics


CoA Therapeutics was founded in 2018 with the aim of harnessing advances in understanding of the CoA pathway to develop novel therapies for difficult to treat and rare genetic disorders.

Industries

Employees

1-10

Links


Org chart

Christine Siu
Chief Operating Officer
Collapse
Anna Wade
VP, BD & Operations
Agnieszka Jurecka
VP, Clinical Development
Jennifer Pavillard
Head Of Regulatory Affairs
Mallory E. Harden
Senior Director | BD And Operations